Flutter Entertainment has become Cure Leukaemia’s first global corporate partner under an expanded three-year commitment.
Building on Flutter’s long-standing support for the charity, the renewed and extended partnership runs until 2028 and significantly enhances the scale and global reach of its fundraising and impact.
The new agreement is expected to generate $1.3 million (or £1 million) a year for Cure Leukaemia, supporting six major clinical trials already primed for delivery and allowing expansion of the globally significant Trials Acceleration Program from 15 centers to 25.
Flutter’s financial commitment will also secure funding of the complementary IMPACT networks – one of only two transplant and cell therapy trials networks in the world – and the recently established MyeCare Registry generating real world data on UK patients with acute myeloid leukaemia.
“This partnership brings together two things that matter deeply to our people,” said Kerry McNally, group head of communities and engagement for Flutter. “The power of sport to bring communities together and the belief that everyone deserves access to better health outcomes.
“What makes this so powerful is that it is driven by our colleagues. Their energy, commitment, and willingness to push themselves to make a difference. Becoming Cure Leukaemia’s first global partner allows us to scale that collective effort and deliver real impact for patients around the world.”
Since its inception in 2023, the partnership has already raised more than $2.7 million in new funding for the blood cancer-focused charity, driven by colleague participation in endurance events and headline sponsorship of the charity’s The Tour 21 and London2Paris events.
As a new global partner, Flutter will continue as headline supporter of these cycling initiatives, while expanding the partnership globally through the launch of the Cure Leukaemia Running Club.
This will offer Flutter’s 29,000 employees across more than 30 countries the opportunity to take part in flagship marathon and other running events, virtual challenges, and community fundraising initiatives worldwide.
The addition of running-focused initiatives will directly contribute to funding two clinical trials per year and support specialist clinical trials nurses in ten new centers.
Cure Leukaemia CEO James McLaughlin said: “Flutter’s support since 2023 has been of pivotal importance in funding pioneering clinical trials with the potential to transform the lives of blood cancer patients across the UK. What has been especially striking is the way colleagues from Flutter have consistently fronted up, with passion, energy, and commitment for our cause.
“Their collective effort has been instrumental to our impact so far, and this new global commitment will allow us to run more trials, expand the Trials Acceleration Program, and reach more families who urgently need access to the latest treatments. In December 2025, a number of globally impacting clinical trials were presented at the American Society of Haematology Conference, including the AMMO trial, which is supported through the Trials Acceleration Program, demonstrating the global impact and importance of Flutter’s continued support.”
Shares in Flutter Entertainment plc (NYSE:FLUT) closed 2.88 per cent lower at $149.47 per share in New York Friday.